参松养心胶囊降低房颤消融术后复发的系统评价与Meta分析
该系统评价纳入9项RCT共2199例首次房颤消融术后患者,评估参松养心胶囊联合抗心律失常药的疗效与安全性。结果显示联合治疗使总体房颤人群早期复发风险降低45%(RR 0.55),持续性房颤晚期复发降低38%(RR 0.62),不良事件无显著差异,证据等级为中至低。
要点
- 参松养心胶囊联合AAD可降低总体房颤人群消融术后早期复发风险。
- 对持续性房颤患者,联合治疗可降低晚期复发风险。
- 不良事件发生率与对照组无统计学显著差异。
核心结论
- AAD联合参松养心胶囊可安全有效降低总体房颤人群消融术后早期复发,并仅对持续性房颤降低晚期复发。
- 该证据提示参松养心胶囊可作为房颤消融术后潜在的辅助治疗选择,但外推至西方人群需谨慎。
研究设计与样本
- 系统检索八个数据库至2025年7月1日,纳入首次房颤消融术后使用参松养心胶囊的RCT。
- 共纳入9项研究、2199例患者,主要结局为房颤复发,并评估安全性终点。
- 采用GRADE框架评估证据质量,方案在PROSPERO前瞻性注册(CRD420251012453)。
主要发现
- AAD联合参松养心胶囊使总体房颤人群早期复发风险降低45%(RR 0.55,95% CI:0.42至0.71,P < 0.001;I2 = 0%)。
- 在持续性房颤中,联合治疗使晚期复发风险降低38%(RR 0.62,95% CI:0.47至0.81,P < 0.001;I2 = 0%)。
- 参松养心胶囊组与对照组不良事件发生率无统计学显著差异。
- 晚期复发和早期复发的证据等级分别为中度和低度。
关键数值与推荐
- 早期复发:总体房颤人群RR 0.55(95% CI:0.42至0.71,P < 0.001;I2 = 0%)。
- 晚期复发:持续性房颤RR 0.62(95% CI:0.47至0.81,P < 0.001;I2 = 0%)。
- 证据质量:晚期复发为中度,早期复发为低度。
临床怎么用
- 对首次房颤消融术后患者,可考虑在AAD基础上联用参松养心胶囊以降低早期复发。
- 对持续性房颤患者,联用参松养心胶囊可能有助于降低晚期复发。
- 联合治疗未观察到不良事件发生率的统计学显著增加。
局限性
- 证据质量分别为中度和低度,提示对效应估计的把握有限。
- 外推至西方人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Shensong Yangxin (SSYX) capsule, a well-known Chinese patent medicine, is widely applied in the treatment of atrial fibrillation (AF). AIM OF THE STUDY: To determine the efficacy and safety of SSYX as adjunctive therapy on recurrence after ablation in AF patients. MATERIALS AND METHODS: A systematic search was conducted across eight databases to identify randomized controlled trials (RCTs) involving SSYX therapy after first AF ablation until 1st July 2025. The primary outcome was AF recurrence, and safety endpoint was also examined. The quality of evidence was assessed using the GRADE framework. The protocol was prospectively registered on PROSPERO (CRD420251012453). RESULTS: Nine studies comprising 2199 patients were included. Anti-arrhythmic drugs (AADs) plus SSYX reduced early recurrence by 45% (RR 0.55, 95% CI: 0.42 to 0.71, P < 0.001; I2 = 0%) in overall AF populations, and late recurrence by 38% (RR 0.62, 95% CI: 0.47 to 0.81, P < 0.001; I2 = 0%) in persistent AF. Moreover, no statistically significant difference was observed in the incidence of adverse events between SSYX and control groups. A moderate and low level of evidence were identified for late and early recurrence, separately. CONCLUSION: Combination therapy with AAD and SSYX after ablation could safely and effectively reduce early recurrence across AF populations and late recurrence only for persistent AF. This evidence highlights the potential of SSYX as a potential adjuvant treatment option after AF ablation. However, extrapolation to Western populations requires caution.
引用
- Mao T, Li Y, Chen J, et al. A systematic review and meta-analysis of randomized controlled trials on the efficacy of Shensong Yangxin capsule for recurrence of atrial fibrillation after catheter ablation. J Ethnopharmacol. 2026. PMID: 42219066. doi:10.1016/j.jep.2026.121928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。